The efficacy of a single intraperitoneal injection of oxolinic acid in the treatment of bacterial infections in goldsinny wrasse (Ctenolabrus rupestris) and corkwing wrasse (Symphodus melops) studied under field and laboratory conditions.
The efficacy of a single intraperitoneal injection of oxolinic acid to control an outbreak of atypical Aeromonas salmonicida infection in goldsinny wrasse (Ctenolabrus rupestris) and in the treatment of systemic vibriosis in corkwing wrasse (Symphodus melops) was examined. In addition a field study was performed to examine the effect of medication on the survival rate of goldsinny wrasse in Atlantic salmon cages. Four groups of wild caught goldsinny wrasse, each of 50 fish, were treated with an intraperitoneal injection of propylene glycol:saline (50:50) (control) or 50 mg/kg oxolinic acid at a concentration of 50 mg/mL. Three days after medication the fish in all groups were treated by an intraperitoneal injection of prednisolone acetate and an increase in seawater temperature from 9.0 to 11.5 degrees C. Cumulative mortalities were 18% in the two groups treated with oxolinic acid and 94 and 100% in the unmedicated control groups, giving a 'relative percentage survival' (RPS) value of 82%. A laboratory maintained population of originally wild caught corkwing wrasse experiencing high daily mortality was treated with oxolinic acid (50 mg/kg) or propylene glycol:saline (control). Cumulative mortalities were 84% (control) and 42% (oxolinic acid medicated group) giving an RPS value of 50%. In a field investigation using goldsinny wrasse approximately 30% were medicated with oxolinic acid (50 mg/kg) prior to stocking in cages with Atlantic salmon. In two of three cages the cumulative mortality was significantly lower (P = 0.025 and P < 0.001) in the medicated groups.
Samuelsen
O B
OB
Department of Aquaculture, Institute of Marine Research, Bergen, Norway. ole.samuelsen@farm.uib.no
Kvenseth
P G
PG
Andreassen
J H
JH
Torkildsen
L
L
Ervik
A
A
Bergh
O
O
D000333:Aeromonas / Q000187:drug effects*; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005393:Fish Diseases / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D007274:Injections, Intraperitoneal / Q000662:veterinary; D008826:Microbial Sensitivity Tests; D010093:Oxolinic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010473:Perciformes; D016896:Treatment Outcome; D014735:Vibrio Infections / Q000188:drug therapy / Q000662:veterinary*
D000890:Anti-Infective Agents; D010093:Oxolinic Acid